Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
LetterLetter
Open Access

Drs. Cron and Chatham reply

Randy Q. Cron and W. Winn Chatham
The Journal of Rheumatology April 2020, jrheum.200492; DOI: https://doi.org/10.3899/jrheum.200492
Randy Q. Cron
University of Alabama at Birmingham, Department of Pediatrics, Division of Rheumatology; University of Alabama at Birmingham, Department of Medicine, Division of Clinical Immunology and Rheumatology, Birmingham, Alabama, USA. Drs. Cron and Chatham are co-principal investigators on an investigator-initiated clinical trial to study interleukin-1 blockade in treating secondary hemophagocytic lymphohistiocytosis (HLH) in children and adults. The trial is funded by Swedish Orphan Biovitrum Inc. (SOBI; ClinicalTrials.gov: ), which manufactures anakinra. Dr. Cron serves as a consultant to SOBI. Dr. Chatham has served as a consultant to SOBI. Address correspondence to Dr. R.Q. Cron, Children’s of Alabama, Division of Rheumatology, 1600 7th Ave. S., CPPN, Suite G10, Birmingham, AL 35233-1711, USA. E-mail: rcron@peds.uab.edu.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Randy Q. Cron
W. Winn Chatham
University of Alabama at Birmingham, Department of Pediatrics, Division of Rheumatology; University of Alabama at Birmingham, Department of Medicine, Division of Clinical Immunology and Rheumatology, Birmingham, Alabama, USA. Drs. Cron and Chatham are co-principal investigators on an investigator-initiated clinical trial to study interleukin-1 blockade in treating secondary hemophagocytic lymphohistiocytosis (HLH) in children and adults. The trial is funded by Swedish Orphan Biovitrum Inc. (SOBI; ClinicalTrials.gov: ), which manufactures anakinra. Dr. Cron serves as a consultant to SOBI. Dr. Chatham has served as a consultant to SOBI. Address correspondence to Dr. R.Q. Cron, Children’s of Alabama, Division of Rheumatology, 1600 7th Ave. S., CPPN, Suite G10, Birmingham, AL 35233-1711, USA. E-mail: rcron@peds.uab.edu.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

We appreciate our Italian colleagues’ interest in our editorial denoting the rheumatologist’s role in helping to diagnose and treat cytokine storm syndrome (CSS) in the setting of the coronavirus disease 2019 (COVID-19) pandemic1. It is encouraging that none of the 123 pediatric rheumatology patients (primarily juvenile idiopathic arthritis) treated with background biological disease-modifying antirheumatic drug (bDMARD) therapies in Milan, Italy, surveyed over a 7-week period from February 25 through April 14, 2020 (during which time COVID-19 was hyperendemic there), had either confirmed or suspected COVID-192.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 48, Issue 3
1 Mar 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Drs. Cron and Chatham reply
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Drs. Cron and Chatham reply
Randy Q. Cron, W. Winn Chatham
The Journal of Rheumatology Apr 2020, jrheum.200492; DOI: 10.3899/jrheum.200492

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Drs. Cron and Chatham reply
Randy Q. Cron, W. Winn Chatham
The Journal of Rheumatology Apr 2020, jrheum.200492; DOI: 10.3899/jrheum.200492
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • What It Means to Me to Have Juvenile Arthritis: One Patient’s Definition
  • COVID-19 in Patients With Connective Tissue Disease-related Interstitial Lung Disease
  • Clinical and Radiological Remission of Osteoarticular and Cutaneous Lesions in SAPHO Patients Treated With Secukinumab: A Case Series
Show more Letters

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire